Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $3.2 million.

  • Entrada Therapeutics' Capital Expenditures fell 126.76% to -$171,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 46.18%. This contributed to the annual value of $3.2 million for FY2024, which is 43.75% down from last year.
  • Per Entrada Therapeutics' latest filing, its Capital Expenditures stood at $3.2 million for FY2024, which was down 43.75% from $5.6 million recorded in FY2023.
  • Entrada Therapeutics' Capital Expenditures' 5-year high stood at $5.6 million during FY2023, with a 5-year trough of $2.3 million in FY2020.
  • In the last 3 years, Entrada Therapeutics' Capital Expenditures had a median value of $3.2 million in 2024 and averaged $3.9 million.
  • Per our database at Business Quant, Entrada Therapeutics' Capital Expenditures skyrocketed by 97.58% in 2021 and then plummeted by 43.75% in 2024.
  • Over the past 5 years, Entrada Therapeutics' Capital Expenditures (Yearly) stood at $2.3 million in 2020, then skyrocketed by 97.58% to $4.6 million in 2021, then tumbled by 36.97% to $2.9 million in 2022, then soared by 94.46% to $5.6 million in 2023, then slumped by 43.75% to $3.2 million in 2024.